Repligen Corporation, founded in 1981 and headquartered in Waltham, Massachusetts, United States, provides advanced bioprocessing technologies to the global biopharmaceutical industry. The company drives revenue by supplying proprietary reagents, chromatography resins, and single‐use systems to major pharmaceutical firms. Under the leadership of CEO Robert E. Dutton, Repligen has secured an estimated 15-20% market share in its niche through innovative process solutions. It is focused on strategic expansion and R&D investments to fuel double-digit growth in the near term.
Although we do not currently have any customers that represent more than 10% of our consolidated revenues, we have historically depended on a limited number of customers for a high percentage of our revenues; there was no revenue from customers that represented 10% or more of the Company's total revenue for the years ended December 31, 2025, 2024 and 2023.